Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 12/20 | 0.36 |
| ▸ | HTR1A | P08908 | 11/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946230 | 1.00 | CA2 (0.50) | CA2ADRA1DHTR1AADRA1BADRA1A | |
| SCHEMBL1945756 | 1.00 | CA2 (0.50) | CA2ADRA1DHTR1AADRA1BADRA1A | |
| SCHEMBL20689800 | 0.85 | CA2 (0.59) | CA2ADRA1DHTR1AADRA1BADRA1A | |
| SCHEMBL1235933 | 0.84 | CA2 (0.51) | CA2ADRA1DHTR1AADRA1BADRA1A | |
| SCHEMBL10864461 | 0.82 | CA2 (0.54) | CA2ADRA1DHTR1AADRA1BADRA1A | |
| SCHEMBL27821631 | 0.79 | CA2 (0.47) | CA2ADRA1DHTR1AADRA1BADRA1A | |
| SCHEMBL5990159 | 0.77 | CA2 (0.56) | CA2NAMPT | |
| SCHEMBL3500787 | 0.77 | CA2 (0.56) | CA2NAMPT | |
| SCHEMBL6844207 | 0.77 | CA2 (0.56) | CA2NAMPT | |
| SCHEMBL28602350 | 0.76 | CA2 (0.44) | CA2ADRA1DHTR1AADRA1BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| EP-2203189-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-18 | — | — | EP | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| EP-2395005-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | Industrial Research Limited (NZ) | 2011-12-14 | — | — | EP | disclosed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| EP-2205553-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-07-14 | — | — | EP | disclosed |
| EP-2203189-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-07-07 | — | — | EP | disclosed |
| EP-2200656-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | disclosed |
| WO-2008030119-A9 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| EP-2057165-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009047315-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008030119-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | PNP, TYMP, NTPCR | CA2 2335/4885ADRA1D 2886/4885HTR1A 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.